# AZD4360

Source: https://onco.cc/drugs/azd4360/  
OnCo record `azd4360` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

AZD4360 is an experimental antibody-drug conjugate from AstraZeneca in phase 2 trials for gastric & gastro-oesophageal junction cancer, biliary tract cancer and pancreatic ductal adenocarcinoma, aimed at Claudin 18.2.

## Summary

AZD4360 is an antibody-drug conjugate developed by AstraZeneca. Its target is Claudin 18.2 (the sponsor names Claudin 18.2 (CLDN18.2)). The sponsor states: AZD4360 is an antibody-drug conjugate targeting Claudin 18.2, being studied in advanced solid tumours including gastric, gastro-oesophageal junction, biliary tract and pancreatic cancers. ClinicalTrials.gov describes the intervention as: Antibody-Drug Conjugate targeting Claudin 18.2 (CLDN18.2). It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, in gastric & gastro-oesophageal junction cancer, biliary tract cancer and pancreatic ductal adenocarcinoma. The largest, NCT06921928, plans to enrol 31 participants (actual) with primary completion expected 2027-03-31. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.

## Fields

- Kind: Treatment
- Status: phase-2
- Last checked: 2026-09-11
- Tags: pipeline; ctgov-ingest
- Modality: ADC
- Mechanism: AZD4360 is an antibody-drug conjugate targeting Claudin 18.2, being studied in advanced solid tumours including gastric, gastro-oesophageal junction, biliary tract and pancreatic cancers.

## Notes

- 23 Sept 2026: the payload is not stated on any record OnCo reads, so the open drug engine shows AZD4360 under Claudin 18.2 with the payload class not recorded rather than guessing.

## Sources

- ClinicalTrials.gov: trials of AZD4360: https://clinicaltrials.gov/search?intr=AZD4360

## Connected records

- cancers: [Biliary tract cancer (cholangiocarcinoma)](https://onco.cc/cancers/cholangiocarcinoma/), [Gastric & gastro-oesophageal junction cancer](https://onco.cc/cancers/gastric/), [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)
- targets: [Claudin 18.2](https://onco.cc/targets/cldn18-2/)
- companies: [AstraZeneca](https://onco.cc/companies/astrazeneca/)
- trials: [Study for AZD4360 in Participants With Advanced Solid Tumours](https://onco.cc/trials/nct06921928/)

---
JSON: https://onco.cc/api/v1/entities/azd4360.json